This article is
- freely available
Metallo-β-Lactamases and Aptamer-Based Inhibition
Department of Chemistry and Biochemistry and the Institute of Biomedical Studies, Baylor University, Waco, TX 76798, USA
* Author to whom correspondence should be addressed.
Received: 14 January 2011; in revised form: 8 February 2011 / Accepted: 16 February 2011 / Published: 18 February 2011
Abstract: An evolution of antibiotic-resistant bacteria has resulted in the need for new antibiotics. β-Lactam based drugs are the most predominantly prescribed antibiotics to combat bacterial infections; however, production of β-lactamases, which catalyze the hydrolysis of the β-lactam bond of this class of antibiotics, by pathogenic bacteria such as Bacillus cereus, are rendering them useless. Some inhibitors of β-lactamases have been found, but there are no inhibitors against a class of β-lactamases known as metallo-β-lactamases, and it has been reported that the number of bacteria that produce metallo-β-lactamases is on the rise. Finding inhibitors of metallo-β-lactamases is thus an urgent necessity. One way to approach the problem is by employing the combinatorial method SELEX. The SELEX method is significant in discovering and producing new classes of inhibitors, as well as providing insight into the development of these inhibitors and paves the way for future aptamer applications that further novel drug discovery.
Keywords: metallo-β-lactamase; aptamer; SELEX; inhibitor; Bacillus cereus
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Schlesinger, S.R.; Lahousse, M.J.; Foster, T.O.; Kim, S.-K. Metallo-β-Lactamases and Aptamer-Based Inhibition. Pharmaceuticals 2011, 4, 419-428.
Schlesinger SR, Lahousse MJ, Foster TO, Kim S-K. Metallo-β-Lactamases and Aptamer-Based Inhibition. Pharmaceuticals. 2011; 4(2):419-428.
Schlesinger, Sara R.; Lahousse, Mieke J.; Foster, Taylor O.; Kim, Sung-Kun. 2011. "Metallo-β-Lactamases and Aptamer-Based Inhibition." Pharmaceuticals 4, no. 2: 419-428.